Oleanolic acid modulates the immune-inflammatory response in mice with experimental autoimmune myocarditis and protects from cardiac injury. Therapeutic implications for the human disease

Journal of Molecular and Cellular Cardiology

Volumn 72, Issue , 2014, Pages 250-262

  Martin R ^a   Cordova, C ^b   San Roman J A ^a   Gutierrez, B ^b   Cachofeiro, V ^c   Nieto, M L ^b  

^a HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^b UNIVERSITY OF VALLADOLID   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

Calcification; Fibrosis; Inflammation; Myocarditis; Oleanolic acid; Triterpenes

Indexed keywords

AUTOANTIBODY; BRAIN NATRIURETIC PEPTIDE; CALCIUM; CARDIAC MYOSIN; COLLAGEN; INTERLEUKIN 10; INTERLEUKIN 35; MYOSIN HEAVY CHAIN ALPHA; OLEANOLIC ACID; CARDIOTONIC AGENT; INTERLEUKIN DERIVATIVE; INTERLEUKIN-35, MOUSE; MYH6 PROTEIN, MOUSE; MYOSIN HEAVY CHAIN; PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ARTICLE; AUTOIMMUNE DISEASE; BODY WEIGHT; CALCINOSIS; CARDIOVASCULAR INFLAMMATION; CELL INFILTRATION; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DISEASE MODEL; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; EXPERIMENTAL AUTOIMMUNE MYOCARDITIS; FEMALE; FIBROBLAST; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART WEIGHT; HISTOPATHOLOGY; IMMUNIZATION; IMMUNOMODULATION; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE COUNT; MALE; MOUSE; MYOCARDITIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGULATORY T LYMPHOCYTE; ANIMAL; AUTOIMMUNE DISEASES; BAGG ALBINO MOUSE; BIOSYNTHESIS; BLOOD; CARDIOMYOPATHY, DILATED; CHEMICALLY INDUCED; HEART MUSCLE; HUMAN; IMMUNOLOGY; METABOLISM; ORGAN SIZE; PATHOLOGY;

ANIMALS; AUTOANTIBODIES; AUTOIMMUNE DISEASES; BODY WEIGHT; CALCIUM; CARDIOMYOPATHY, DILATED; CARDIOTONIC AGENTS; CELL PROLIFERATION; FEMALE; FIBROBLASTS; HUMANS; IMMUNOMODULATION; INTERLEUKIN-10; INTERLEUKINS; MALE; MICE; MICE, INBRED BALB C; MYOCARDITIS; MYOCARDIUM; MYOSIN HEAVY CHAINS; NATRIURETIC PEPTIDE, BRAIN; OLEANOLIC ACID; ORGAN SIZE; PEPTIDES; T-LYMPHOCYTES, REGULATORY;

EID: 84901330495     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2014.04.002     Document Type: Article

References (41)

1. Caforio A.L., Goldman J.H., Haven A.J., Baig K.M., McKenna W.J. Evidence for autoimmunity to myosin and other heart-specific autoantigens in patients with dilated cardiomyopathy and their relatives. Int J Cardiol 1996, 54:157-163.
2. Brown C.A., O'Connell J.B. Myocarditis and idiopathic dilated cardiomyopathy. Am J Med 1995, 99:309-314.
3. Drory Y., Turetz Y., Hiss Y., Lev B., Fisman E.Z., Pines A., et al. Sudden unexpected death in persons less than 40years of age. Am J Cardiol 1991, 68:1388-1392.
4. Lauer B., Schannwell M., Kuhl U., Strauer B.E., Schultheiss H.P. Antimyosin autoantibodies are associated with deterioration of systolic and diastolic left ventricular function in patients with chronic myocarditis. J Am Coll Cardiol 2000, 35:11-18.
5. Cihakova D., Rose N.R. Pathogenesis of myocarditis and dilated cardiomyopathy. Adv Immunol 2008, 99:95-114.
6. Eriksson U., Penninger J.M. Medicine in focus: autoimmune heart failure: new understanding of pathogenesis. Int J Biochem Cell Biol 2005, 37:27-32.
7. Frustaci A., Chimenti C., Calabrese F., Pieroni M., Thiene G., Maseri A. Immunosuppressive therapy for active lymphocytic myocarditis: virological and immunologic profile of responders vs. non-responders. Circulation 2003, 107:857-863.
8. Neu N., Rose N.R., Beisel K.W., Herskowitz A., Gurri-Glass G., Craig S.W. Cardiac myosin induces myocarditis in genetically predisposed mice. J Immunol 1987, 139:3630-3636.
9. Pummerer C.L., Luze K., Grassl G., Bachmaier K., Offner F., Burrell S.K., et al. Identification of cardiac myosin peptides capable of inducing autoimmune myocarditis in BALB/c mice. J Clin Invest 1996, 97:2057-2062.
10. Smith S.C., Allen P.M. Myosin-induced acute myocarditis is a T cell-mediated disease. J Immunol 1991, 147:2141-2147.
11. Liu J. Oleanolic acid and ursolic acid: research perspectives. J Ethnopharmacol 2005, 100:92-94.
12. Dzubak P., Hajduch M., Vydra D., Hustova A., Kvasnica M., Biedermann D., et al. Pharmacological activities of natural triterpenoids and their therapeutic implications. Nat Prod Rep 2006, 23:394-411.
13. Ríos J.L. Effects of triterpenes on the immune system. J Ethnopharmacol 2010, 128:1-14.
14. Martín R., Carvalho-Tavares J., Hernández M., Arnés M., Ruiz-Gutiérrez V., Nieto M.L. Beneficial actions of oleanolic acid in an experimental model of multiple sclerosis: a potential therapeutic role. Biochem Pharmacol 2010, 79:198-208.
15. Dumont M., Wille E., Calingasan N.Y., Tampellini D., Williams C., Gouras G.K., et al. Triterpenoid CDDO-methylamide improves memory and decreases amyloid plaques in a transgenic mouse model of Alzheimer's disease. J Neurochem 2009, 109:502-512.
16. Santos R.S., Silva P.L., Oliveira G.P., Cruz F.F., Ornellas D.S., Morales M.M., et al. Effects of oleanolic acid on pulmonary morphofunctional and biochemical variables in experimental acute lung injury. Respir Physiol Neurobiol 2011, 179:129-136.
17. Senthil S., Sridevi M., Pugalendi K.V. Cardioprotective effect of oleanolic acid on isoproterenol-induced myocardial ischemia in rats. Toxicol Pathol 2007, 35:418-423.
18. Buus N.H., Hansson N.C., Rodriguez-Rodriguez R., Stankevicius E., Andersen M.R., Simonsen U. Antiatherogenic effects of oleanolic acid in apolipoprotein E knockout mice. Eur J Pharmacol 2011, 670:519-526.
19. Kamal F.A., Watanabe K., Ma M., Abe Y., Elbarbary R., Kodama M., et al. A novel phenylpyridazinone, T-3999, reduces the progression of autoimmune myocarditis to dilated cardiomyopathy. Heart Vessels 2011, 26:81-90.
20. Lopez-Andrès N., Rossignol P., Iraqi W., Fay R., Nuée J., Ghio S., et al. Association of galectin-3 and fibrosis markers with long-term cardiovascular outcomes in patients with heart failure, left ventricular dysfunction, and dyssynchrony: insights from the CARE-HF (Cardiac Resynchronization in Heart Failure) trial. Eur J Heart Fail 2012, 14:74-81.
21. Anand I.S., Rector T.S., Kuskowski M., Adourian A., Muntendam P., Cohn J.N. Baseline and serial measurements of galectin-3 in patients with heart failure: relationship to prognosis and effect of treatment with valsartan in the Val-HeFT. Eur J Heart Fail 2013, 15:511-518.
22. Pereira D.A., Dalmarco J.B., Wisniewski A., Simionatto E.L., Pizzolatti M.G., Fröde T.S. Lotus corniculatus regulates the inflammation induced by bradykinin in a murine model of pleurisy. J Agric Food Chem 2011, 59:2291-2298.
23. Raphael T.J., Kuttan G. Effect of naturally occurring triterpenoids glycyrrhizic acid, ursolic acid, oleanolic acid and nomilin on the immune system. Phytomedicine 2003, 10:483-489.
24. Afanasyeva M., Wang Y., Kaya Z., Park S., Zilliox M.J., Schofield B.H., et al. Experimental autoimmune myocarditis in A/J mice is an interleukin-4-dependent disease with a Th2 phenotype. Am J Pathol 2001, 159:193-203.
25. Bahk T.J., Daniels M.D., Leon J.S., Wang K., Engman D.M. Comparison of angiotensin converting enzyme inhibition and angiotensin II receptor blockade for the prevention of experimental autoimmune myocarditis. Int J Cardiol 2008, 125:85-93.
26. Malkiel S., Factor S., Diamon B. Autoimmune myocarditis does not require B cells for antigen presentation. J Immunol 1999, 163:5265-5268.
27. Eriksson U., Kurrer M.O., Schmitz N., Marsch S.C., Fontana A., Eugster H.P., et al. Interleukin-6-deficient mice resist development of autoimmune myocarditis associated with impaired upregulation of complement C3. Circulation 2003, 107:320-325.
28. Rose N.R. Critical cytokine pathways to cardiac inflammation. J Interferon Cytokine Res 2011, 31:705-710.
29. Baldeviano G.C., Barin J.G., Talor M.V., Srinivasan S., Bedja D., Zheng D., et al. Interleukin-17A is dispensable for myocarditis but essential for the progression to dilated cardiomyopathy. Circ Res 2010, 106:1646-1655.
30. Nishio R., Matsumori A., Shioi T., Ishida H., Sasayama S. Treatment of experimental viral myocarditis with interleukin-10. Circulation 1999, 100:1102-1108.
31. O'Garra A., Vieira P.L., Vieira P., Goldfeld A.E. IL-10-producing and naturally occurring CD4+ Tregs: limiting collateral damage. J Clin Invest 2004, 114:1372-1378.
32. Chaturvedi V., Collison L.W., Guy C.S., Workman C.J., Vignali D.A. Cutting edge: human regulatory T cells require IL-35 to mediate suppression and infectious tolerance. J Immunol 2011, 186:6661-6666.
33. Kochetkova I., Golden S., Holderness K., Callis G., Pascual D.W. IL-35 stimulation of CD39+regulatory T cells confers protection against collagen II-induced arthritis via the production of IL-10. J Immunol 2010, 184:7144-7153.
34. Soares M., Lima R.S., Souza B., Vasconcelos J.F., Rocha L.L., Dos Santos R.R., et al. Reversion of gene expression alterations in hearts of mice with chronic chagasic cardiomyopathy after transplantation of bone marrow cells. Cell Cycle 2011, 10:1448-1455.
35. Jiang H.R., Al Rasebi Z., Mensah-Brown E., Shahin A., Xu D., Goodyear C.S., et al. Galectin-3 deficiency reduces the severity of experimental autoimmune encephalomyelitis. J Immunol 2009, 182:1167-1167.
36. Zhu H., Shan L., Schiller P.W., Mai A., Peng T. Histone deacetylase-3 activation promotes tumor necrosis factor-α (TNF-α) expression in cardiomyocytes during lipopolysaccharide stimulation. J Biol Chem 2010, 285:9429-9436.
37. Oppeltz R.F., Zhang Q., Rani M., Sasaki J.R., Schwacha M.G. Increased expression of cardiac IL-17 after burn. J Inflamm 2010, 7:38.
38. Dinkova-Kostova A.T., Liby K.T., Stephenson K.K., Holtzclaw W.D., Gao X., Suh N., et al. Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress. Proc Natl Acad Sci U S A 2005, 102:4584-4589.
39. Yunoki K., Sasaki G., Tokuji Y., Kinoshita M., Naito A., Aida K., et al. Effect of dietary wine pomace extract and oleanolic acid on plasma lipids in rats fed high-fat diet and its DNA microarray analysis. J Agric Food Chem 2008, 56:12052-12058.
40. Liu C., Li Y., Zuo G., Xu W., Gao H., Yang Y., et al. Oleanolic acid diminishes liquid fructose-induced Fatty liver in rats: role of modulation of hepatic sterol regulatory element-binding protein-1c-mediated expression of genes responsible for de novo Fatty Acid synthesis. Evid Based Complement Altern Med 2013, 2013:534084.
41. Dubey V.K., Patil C.R., Kamble S.M., Tidke P.S., Patil K.R., Maniya P.J., et al. Oleanolic acid prevents progression of streptozotocin induced diabetic nephropathy and protects renal microstructures in Sprague Dawley rats. J Pharmacol Pharmacother 2013, 4:47-52.